Case series of sebelipase alfa hypersensitivity reactions and successful sebelipase alfa rapid desensitization
Michelle F. Huffaker,
Anne Y. Liu,
Gregory M. Enns,
Suresh Vijay,
Antonio J. Amor,
N. Franklin Adkinson Jr
Affiliations
Michelle F. Huffaker
Division of Allergy, Immunology, & Rheumatology, Department of Pediatrics Stanford University Stanford California
Anne Y. Liu
Division of Allergy, Immunology, & Rheumatology, Department of Pediatrics Stanford University Stanford California
Gregory M. Enns
Division of Allergy, Immunology, & Rheumatology, Department of Pediatrics Stanford University Stanford California
Suresh Vijay
Birmingham Children's Hospital NHS Foundation Trust Birmingham UK
Antonio J. Amor
Endocrinology and Nutrition Department, Institut d'Investigacions Biomèdiques August Pi i Sunyer, Hospital Clínic University of Barcelona Barcelona Spain
N. Franklin Adkinson Jr
Johns Hopkins Asthma & Allergy Center Baltimore Maryland
Abstract Allergic immune‐mediated hypersensitivity reactions are known potential complications of enzyme replacement therapy. Sebelipase alfa, recombinant lysosomal acid lipase (LAL), is a potentially life‐altering treatment for patients with LAL deficiency. There is very little information on the diagnosis and management of immediate hypersensitivity reactions to this drug. Here we present three unique cases of hypersensitivity reactions to sebelipase alfa, spanning a broad age spectrum from infancy to adulthood, each managed with successful rapid desensitization.
